-
00:00
1.
index 1
-
00:23
2.
Title
-
01:40
3.
About Breast Cancer
-
03:16
4.
Triple Negative Breast Cancer Subtype
-
04:09
5.
FUSCC TNBC Subtype
-
05:16
6.
FUSCC TNBC Subtype
-
06:21
7.
Luminal Androgen Receptor LAR
-
07:22
8.
Immunomodulatory IM
-
08:09
9.
Basal-like Immune-suppressed BLIS
-
09:22
10.
Mesenchymal-like MES
-
10:13
11.
FUTURE clinical trial
-
11:02
12.
Slide 12
-
11:46
13.
Metabolic Dysregulation in TNBCs
-
13:25
14.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
14:20
15.
Metabolic-Pathway-Based Stratification of TNBC
-
15:30
16.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
16:51
17.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
17:23
18.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
18:28
19.
Slide 20
-
19:51
20.
The Metabolomic Landscape of TNBC
-
20:42
21.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
22:19
22.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
23:38
23.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
24:43
24.
Slide 26
-
25:18
25.
Ferroptosis
-
26:14
26.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
27:03
27.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
28:05
28.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
28:42
29.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
29:58
30.
Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
-
31:01
31.
Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
-
31:35
32.
AR is the key regulator of GPX4 expression in LAR tumors
-
32:33
33.
AR is the key regulator of GPX4 expression in LAR tumors
-
33:43
34.
AR Binds to the GPX4 Promoter and Drives its Expression
-
34:23
35.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
35:42
36.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
37:19
37.
GPX4 Inhibitors Diminish Tumor Growth In Vivo
-
38:38
38.
Slide 40
-
39:37
39.
Slide 41
-
40:31
40.
Slide 40
-
45:25
41.
Polar Metabolite and Lipid Profiling of TNBC
-
45:36
42.
The Metabolomic Landscape of TNBC
-
46:14
43.
Metabolic-Pathway-Based Stratification of TNBC
-
47:25
44.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
50:47
45.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
51:05
46.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
51:06
47.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
51:07
48.
Ferroptosis
-
51:07
49.
Slide 26
-
51:08
50.
Ferroptosis
-
55:36
51.
About Breast Cancer
-
56:13
52.
** after 1112seminar.pptx
-
56:15
53.
About Breast Cancer
-
56:17
54.
Triple Negative Breast Cancer Subtype
-
56:18
55.
FUSCC TNBC Subtype
-
56:18
56.
FUSCC TNBC Subtype
-
56:19
57.
Luminal Androgen Receptor LAR
-
56:19
58.
Immunomodulatory IM
-
56:21
59.
Basal-like Immune-suppressed BLIS
-
56:22
60.
Mesenchymal-like MES
-
56:22
61.
Basal-like Immune-suppressed BLIS
-
56:23
62.
Immunomodulatory IM
-
56:26
63.
Luminal Androgen Receptor LAR
-
56:27
64.
FUSCC TNBC Subtype
-
56:27
65.
Luminal Androgen Receptor LAR
-
56:28
66.
Immunomodulatory IM
-
56:28
67.
Basal-like Immune-suppressed BLIS
-
56:29
68.
Mesenchymal-like MES
-
56:30
69.
Basal-like Immune-suppressed BLIS
-
56:30
70.
Immunomodulatory IM
-
56:31
71.
Luminal Androgen Receptor LAR
-
57:11
72.
Immunomodulatory IM
-
57:12
73.
Basal-like Immune-suppressed BLIS
-
57:12
74.
Mesenchymal-like MES
-
57:14
75.
FUTURE clinical trial
-
57:15
76.
Slide 12
-
57:16
77.
Metabolic Dysregulation in TNBCs
-
57:19
78.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
57:26
79.
Metabolic Dysregulation in TNBCs
-
57:30
80.
About Breast Cancer
-
58:17
81.
Triple Negative Breast Cancer Subtype
-
58:17
82.
FUSCC TNBC Subtype
-
58:41
83.
FUSCC TNBC Subtype
-
58:42
84.
Luminal Androgen Receptor LAR
-
58:42
85.
Immunomodulatory IM
-
58:43
86.
Basal-like Immune-suppressed BLIS
-
58:43
87.
Mesenchymal-like MES
-
58:44
88.
FUTURE clinical trial
-
1:00:55
89.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:01:02
90.
Metabolic-Pathway-Based Stratification of TNBC
-
1:01:04
91.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:01:11
92.
Metabolic-Pathway-Based Stratification of TNBC
-
1:01:15
93.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:03:45
94.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:03:48
95.
The Metabolomic Landscape of TNBC
-
1:04:45
96.
Slide 20
-
1:04:47
97.
The Metabolomic Landscape of TNBC
-
1:04:52
98.
Slide 20
-
1:04:54
99.
Polar Metabolite and Lipid Profiling of TNBC
-
1:05:21
100.
The Metabolomic Landscape of TNBC
-
1:05:23
101.
Polar Metabolite and Lipid Profiling of TNBC
-
1:05:23
102.
The Metabolomic Landscape of TNBC
-
1:05:24
103.
Polar Metabolite and Lipid Profiling of TNBC
-
1:05:32
104.
The Metabolomic Landscape of TNBC
-
1:05:33
105.
Polar Metabolite and Lipid Profiling of TNBC
-
1:05:39
106.
The Metabolomic Landscape of TNBC
-
1:05:48
107.
Polar Metabolite and Lipid Profiling of TNBC
-
1:05:49
108.
Slide 20
-
1:05:50
109.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:05:50
110.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:05:51
111.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:05:52
112.
Metabolic-Pathway-Based Stratification of TNBC
-
1:06:08
113.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
1:06:17
114.
Metabolic-Pathway-Based Stratification of TNBC
-
1:06:44
115.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
1:06:44
116.
Metabolic Dysregulation in TNBCs
-
1:06:45
117.
Slide 12
-
1:06:46
118.
FUTURE clinical trial
-
1:06:46
119.
Slide 12
-
1:07:03
120.
Metabolic Dysregulation in TNBCs
-
1:07:04
121.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
1:07:04
122.
Metabolic-Pathway-Based Stratification of TNBC
-
1:08:04
123.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
1:09:47
124.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
1:09:54
125.
AR Binds to the GPX4 Promoter and Drives its Expression
-
1:09:56
126.
AR is the key regulator of GPX4 expression in LAR tumors
-
1:10:11
127.
AR Binds to the GPX4 Promoter and Drives its Expression
-
1:10:12
128.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
1:10:12
129.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
1:12:11
130.
Slide 40
-
1:13:17
131.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
1:15:14
132.
FUSCC TNBC Subtype
-
1:15:22
133.
Luminal Androgen Receptor LAR
-
1:15:23
134.
Immunomodulatory IM
-
1:15:24
135.
Basal-like Immune-suppressed BLIS
-
1:15:25
136.
Mesenchymal-like MES
-
1:15:26
137.
FUTURE clinical trial
-
1:15:55
138.
Mesenchymal-like MES
-
1:15:55
139.
Basal-like Immune-suppressed BLIS
-
1:15:56
140.
Immunomodulatory IM
-
1:15:56
141.
Luminal Androgen Receptor LAR
-
1:15:57
142.
FUSCC TNBC Subtype
-
1:15:57
143.
FUSCC TNBC Subtype
-
1:15:58
144.
Triple Negative Breast Cancer Subtype
-
1:15:59
145.
About Breast Cancer
-
1:16:00
146.
Title
-
1:16:18
147.
About Breast Cancer
-
1:16:28
148.
Triple Negative Breast Cancer Subtype
-
1:16:29
149.
FUSCC TNBC Subtype
-
1:16:32
150.
Triple Negative Breast Cancer Subtype
-
1:17:20
151.
FUSCC TNBC Subtype
-
1:18:16
152.
FUSCC TNBC Subtype
-
1:18:44
153.
Luminal Androgen Receptor LAR
-
1:19:09
154.
Immunomodulatory IM
-
1:19:09
155.
Basal-like Immune-suppressed BLIS
-
1:19:46
156.
Mesenchymal-like MES
-
1:20:09
157.
FUTURE clinical trial
-
1:20:28
158.
Slide 12
-
1:21:03
159.
Metabolic Dysregulation in TNBCs
-
1:21:04
160.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
1:21:04
161.
Metabolic-Pathway-Based Stratification of TNBC
-
1:21:36
162.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:21:37
163.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:21:38
164.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:08
165.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:09
166.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:16
167.
Slide 20
-
1:22:36
168.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:37
169.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:38
170.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:22:39
171.
Metabolic-Pathway-Based Stratification of TNBC
-
1:22:39
172.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:24:25
173.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:24:27
174.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
1:24:32
175.
Slide 26
-
1:24:37
176.
Ferroptosis
-
1:25:19
177.
AR is the key regulator of GPX4 expression in LAR tumors
-
1:25:52
178.
AR Binds to the GPX4 Promoter and Drives its Expression
-
1:25:53
179.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
1:25:53
180.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
1:27:20
181.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
1:28:13
182.
GPX4 Inhibitors Diminish Tumor Growth In Vivo
-
1:34:00
183.
** after 1112seminar.pptx